Stanford Researchers Identify New Alzheimer's Drug Target in Tau Protein
Stanford Medicine researchers have discovered a new mechanism by which the tau protein, a central target in Alzheimer's drug development, damages brain cells. The study, published in Neuron, reveals that tau infiltrates mitochondria, reversing the normal electron flow, which generates reactive oxygen species, cellular stress, and inflammation. This discovery shifts the focus from amyloid beta plaques to tau, as tau pathology correlates more closely with cognitive decline. The research suggests that blocking this reversal can reduce neurodegeneration and improve learning and memory in animal models. The study highlights the potential for tau-targeting therapies to address multiple neurodegenerative diseases, including frontotemporal dementia. 
